Human BioSystems to Receive its 4th U.S. Patent: 'Preservation of Blood Platelets with Citrate'
TUESDAY, MAY 16, 2006 11:49 AM
- Market Wire
0.205 -0.025 News
PALO ALTO, CALIFORNIA, May 16, 2006 (MARKET WIRE via COMTEX) -- On the heels of its earlier announcement regarding the receipt of a third patent (U.S. Patent #7,029,839: "Methods & Solutions for Storing Donor Organs"), Human BioSystems (HBSC) announced today that it has been notified by the U.S. Patent Office that it will receive an additional patent titled "Preservation of Blood Platelets with Citrate". This patent grant further adds to the Company's increasing technology base covering a variety of cell preservation methods.
The two major recipient groups for blood platelets are cancer patients that have undergone chemotherapy and/or radiation treatment (about 70%), and trauma patients suffering from extensive bleeding.
"This new patent covers the process of cooling blood platelets to near zero degrees Centigrade to keep them fresh and preserved for greater than the current standard of 5 days. We anticipate being able to extend this process to 7 days and beyond. This will reduce the current need to discard stored platelets that have been preserved by existing methods," explained Dr. David Winter, President of Human BioSystems.
Current technology provides for the storage of platelets at room temperature. This allows any bacteria present to grow rapidly over the current 5-day allowable shelf period.
"By developing a cooling method that prolongs the preservation of platelets, we greatly reduce the risk of bacterial infection while increasing the availability of essential medical resources required to treat cancer and trauma patients," Dr. Winter stated.
Human BioSystems is a developer of preservation platforms for organs and other biomaterials. The Company, which is headquartered in Palo Alto, California with research facilities in Michigan, has made tremendous progress in its nine-year history. This fourth patent is another milestone for Human BioSystems. The Company is also currently conducting tests with two independent and FDA approved laboratories on its proprietary preservation methods.
Certain statements contained herein are "forward-looking'' statements (as such term is defined in the Private Securities Litigation Reform Act of 1995). Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, results from ongoing research and development as well as clinical studies, failure to obtain regulatory approval for the Company's products, if required, failure to develop a product based on the Company's technology, failure of any such products to compete effectively with existing products, the inability to find a strategic partner or to consummate a relationship with a potential strategic partner on acceptable terms, and other factors discussed in filings made by the Company with the Securities and Exchange Commission.
Concept Communications, LLC
James D. Caldwell
SOURCE: Human BioSystems
Copyright 2006 Market Wire, All rights reserved.